First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab MOST POPULAR Hugh Jackman Stops His Show To Bring Woman With Breast Cancer... August 26, 2019 Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... November 21, 2020 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient... May 31, 2024 Load more HOT NEWS Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity... AI is impacting cancer care, but also the environment Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but...
